1. Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
- Author
-
Lin KY, Sun HY, Yang CJ, Lu PL, Lee YT, Lee NY, Liou BH, Tang HJ, Lee MH, Wang NC, Chen TC, Hii IM, Huang SH, Lin CY, Tsai CS, Cheng CY, and Hung CC
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Antitubercular Agents therapeutic use, Antitubercular Agents administration & dosage, Antitubercular Agents adverse effects, Drug Therapy, Combination, Heterocyclic Compounds, 4 or More Rings therapeutic use, Heterocyclic Compounds, 4 or More Rings adverse effects, Heterocyclic Compounds, 4 or More Rings administration & dosage, Oxazines therapeutic use, Oxazines administration & dosage, Piperazines therapeutic use, Piperazines adverse effects, Pyridones therapeutic use, Pyridones adverse effects, Treatment Outcome, Anti-Retroviral Agents therapeutic use, Heterocyclic Compounds, 3-Ring therapeutic use, Heterocyclic Compounds, 3-Ring adverse effects, Heterocyclic Compounds, 3-Ring administration & dosage, HIV Infections drug therapy, HIV Infections complications, HIV Integrase Inhibitors therapeutic use, HIV Integrase Inhibitors adverse effects, HIV Integrase Inhibitors administration & dosage, Isoniazid therapeutic use, Isoniazid administration & dosage, Isoniazid adverse effects, Latent Tuberculosis drug therapy, Rifampin analogs & derivatives, Rifampin therapeutic use, Rifampin administration & dosage
- Abstract
Background: Real-world experience with combinations of short-course rifapentine-based regimens and integrase strand-transfer inhibitor-containing antiretroviral therapy (ART) in management of latent tuberculous infection (LTBI) is limited among people with human immunodeficiency virus (PWH)., Methods: From August 2019 to October 2022, PWH receiving 3 months of weekly rifapentine plus isoniazid (3HP) or 1 month of daily rifapentine plus isoniazid (1HP) in combination with ART were included. The primary outcome was virologic response within 12 months after LTBI treatment; secondary outcomes included treatment completion rate and safety of LTBI regimens., Results: During the study period, 479 PWH (94.6% male; median age, 43 years) were included: 142 received 1HP and bictegravir (BIC)-containing regimens (1HP/BIC group), 46 1HP and dolutegravir (DTG)-containing regimens (1HP/DTG group), 38 3HP and BIC-containing regimens (3HP/BIC group), 214 3HP and DTG-containing regimens (3HP/DTG group), 17 1HP and other ART regimens (1HP/others group), and 22 3HP/other ART regimens (3HP/others group). In the intention-to-treat analysis, the proportions of PWH maintaining plasma HIV-1 RNA <200 copies/mL within 12 months after LTBI treatment completion were 96.5% (1HP/BIC), 100% (1HP/DTG), 100% (3HP/BIC), 95.8% (3HP/DTG), 100% (1HP/others), and 100% (3HP/others). The overall completion rates were >80% for all treatment groups, whereas >50% of the included PWH experienced any adverse event. LTBI regimens and ART combinations were not associated with virologic response and completion rate., Conclusions: Combinations of short-course rifapentine-based regimens and integrase strand-transfer inhibitor-containing ART maintained viral suppression for most PWH within 12 months of LTBI treatment completion with low rates of grade 3 or higher adverse events., Competing Interests: Potential conflicts of interest. C. C. H. has received research support from Gilead Sciences and speaker honoraria from Gilead Sciences and served on advisory boards for Gilead Sciences. H. Y. S. has received research support from Gilead Sciences. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF